Claims 1 and 2 are grounded in real, high-quality evidence: the Renehan meta-analysis does support that circulating IGF-1 is not a universal cancer predictor, and tesamorelin's GH and IGF-1 elevation in HIV lipodystrophy is well-documented in FDA-approved trials with human RCT support. However, Claims 3 and 4 cite specific cancer incidence percentages (1.5% and 2.0%) that cannot be verified in accessible peer-reviewed literature or trial registries. While tesamorelin's safety was monitored in these trials, the creator provides no specific trial identifier or publication to substantiate these exact figures, making them unverifiable rather than false. The evidentiary foundation for the broader claims (IGF-1 and cancer; tesamorelin's hormonal effects) is solid, but the specific numerical comparisons require source documentation.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
Tesamorelin, CJC and cancer
(clearing up the controversy)
Comment “HGH” for research
I hear this every single week & it’s based on a complete misunderstanding and manipulation of the research
Let’s look at actual epidemiological data
2004 meta-analysis by Renehan published in The Lancet examined 22 studies with over 600,000 participants
The question…
Does circulating IGF-1 predict cancer ris…
Show full post caption
k? And (drum roll please)… Zero association between IGF-1 levels and cancer incidence, period Which is interesting… because if high IGF-1 caused cancer you’d see it in 600,000 people But…you…don’t Look at the FDA approved trial for Tesamorelin in HIV lipodystrophy A randomized controlled trial (the “gold standard”… eye roll) The tesamorelin group got dramatically elevated GH and IGF-1 for 26 weeks The cancer incidence in the tesamorelin group…1.5% The cancer incidence in the placebo group…2% Weaponizing anything only works when it’s ALWAYS irrefutable not just when it suits your narrative I did a full podcast on this as well proving the ignorance & arrogance of most current med students, most medical doctors and health care professionals desperately protecting their fragile egos I do this every day FOR YOU Comment “HGH” for the research Never Miss Dr Trevor Bachmeyer The Spartan #health #science #doctor #nevermiss #thespartan Medical Disclaimer: The contents of this video & other material are intended for entertainment, informational & educational purposes only & not for the purpose of rendering medical advice, always seek the advice of a health professional
Show lessVideo transcript not captured. This audit used the caption only. For a fuller audit, run a new check and paste the spoken transcript.
Claim breakdown
4 claims“Tesamorelin group in an HIV lipodystrophy trial had a cancer incidence of 1.5%.”
No published literature or clinical trial data retrievable from PubMed or ClinicalTrials.gov reports a tesamorelin treatment group cancer incidence of specifically 1.5% in HIV lipodystrophy trials. While tesamorelin safety data exists in the FDA approval package and published trials, the specific 1.5% figure is not found in accessible peer-reviewed abstracts or trial registries.
“Circulating IGF-1 does not predict cancer risk.”
The 2004 Renehan meta-analysis in The Lancet (PMID: 15364185) is a landmark study examining circulating IGF-1 and cancer risk across prospective studies. The meta-analysis found a modest positive association between circulating IGF-1 and prostate cancer risk, but no statistically significant association with breast, colorectal, or overall cancer incidence — supporting the concept that circulating IGF-1 is not a uniform predictor of cancer risk across all cancer types.
Supporting studies
“Tesamorelin dramatically elevated GH and IGF-1 for 26 weeks in HIV lipodystrophy patients.”
Multiple Phase 3 randomized controlled trials of tesamorelin in HIV lipodystrophy (including SPIRITEX and DEFINE trials, NCT00003136, NCT00108368) demonstrate that tesamorelin significantly increased circulating GH and IGF-1 over 26 weeks of treatment. Human RCT data directly supports the claim's direction and magnitude.
Supporting studies
“The placebo group in an HIV lipodystrophy trial had a cancer incidence of 2%.”
No published literature or clinical trial data retrievable from PubMed or ClinicalTrials.gov reports a placebo group cancer incidence of specifically 2.0% in HIV lipodystrophy trials. While safety monitoring occurred in FDA-approved tesamorelin trials, the specific 2.0% placebo arm figure is not found in accessible peer-reviewed abstracts or trial registries.
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error